SCHEMBL3599501

SCHEMBL3599501

Cc1ccc(-c2ccc3cc(C(=O)O)n(CC(=O)NCCN(C)C4CCCCC4)c3c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.38
HPGD P15428 1/20 0.37
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
CCR2 P41597 1/20 0.36
TP53 P04637 3/20 0.36
MAPT P10636 3/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
MAPK1 P28482 1/20 0.36
F10 P00742 1/20 0.35
CCR9 P51686 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
WNT1 P04628 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13115992 0.94 HPGD (0.38) HPGDGAATSHRTP53MAPT
SCHEMBL3603676 0.91 MTNR1A (0.40) HPGDGAATSHRTP53MAPT
SCHEMBL3609348 0.84 NPC1 (0.40) GPR35TSHRCCR2KDM4EMAPK1
SCHEMBL3602466 0.83 KDM4E (0.44) HPGDGAATSHRTP53MAPT
SCHEMBL3591923 0.81 GRIN2B (0.44) HPGDGAATSHRKMT2APOLB
SCHEMBL3586854 0.81 KDM4E (0.42) HPGDGAATSHRKMT2APOLB
SCHEMBL3596255 0.81 NPC1 (0.46) TP53MAPTKMT2A
SCHEMBL3586995 0.80 KMT2A (0.47) KMT2A
SCHEMBL3609350 0.78 GPR35 (0.39) GPR35CCR2KMT2APOLBCCR9
SCHEMBL3591118 0.78 KDM4E (0.47) HPGDTSHRTP53MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 GPR35 1339/4885HPGD 3386/4885GAA 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.